

# 動物再生医療と産学官連携の今 —ヒトと動物の再生医療は助け合えるのか?—

Current Status of Animal Regenerative Medicine and  
Industry-Academia-Government Collaboration in Japan  
—Where is the path to the cooperation with Human Regenerative Medicine?—

能田 健<sup>1)</sup>✉ 宮崎 茂<sup>2)3)</sup> 枝村 一弥<sup>4)5)</sup>

Ken Noda /Shigeru Miyazaki / Kazuya Edamura

<sup>1)</sup> 農林水産省動物医薬品検査所 再生医療・バイオ医薬品チーム

<sup>2)</sup> (一社)動物再生医療推進協議会(CARM)

<sup>3)</sup> (一財)生物科学安全研究所

<sup>4)</sup> (一社)日本獣医再生医療学会

<sup>5)</sup> 日本大学生物資源科学部獣医学科獣医外科学研究室

<sup>1)</sup> Biotech/Regenerative Medicine Team, National Veterinary Assay Laboratory (NVAL), Ministry of Agriculture, Forestry and Fisheries, Japan

<sup>2)</sup> Consortium for Advancement of Animal Regenerative Medicine (CARM)

<sup>3)</sup> Research Institute for Animal Science in Biochemistry and Toxicology (RIAS)

<sup>4)</sup> The Japanese Society for Veterinary Regenerative Medicine

<sup>5)</sup> Laboratory of Veterinary Surgery, Department of Veterinary Medicine, College of Bioresource Science, Nihon University

✉ ken\_noda560@maff.go.jp

## KEY WORDS

動物再生医療推進協議会(CARM), プレ・コンペティティブ共同研究,  
ガイドライン, 診療実施施設届出, トランスレーショナル・メディシン

## SUMMARY

Animal regenerative medicine is progressing day by day in cooperation with stakeholders nationwide, in terms of scale and depth compared to the other countries in the worlds. Since the enactment of novel regenerative medicine legislation in 2013, numerous activity and efforts have been made for establishing cooperative structure amongst the stakeholders, resulted in a formation of Consortium for Advancement of Animal Regenerative Medicine (CARM) in 2015. Since then, related guidelines and a registration system for animal regenerative medicine hospitals has been developed and implemented, while strengthening the cooperation between CARM and the government. Based on these innovative approaches, regenerative medical practices are being performed against number of diseases including the ones common to humans and animals ; and animal cell-based products have been developed. This article outlines the legal status, industry-academia-government collaboration, current medical practices and translational medicine to explore the path to human and animal regenerative medicine dialogue.